Table 2.
Patients characteristics and outcomes in this meta-analysis
| Author | No of patients | Postmenopausal status (%) | HER2 status | ORR (doublet agents vs single agent) | Median PFS (months, doublet agents vs single agent) | Median OS (months, doublet agents vs single agent) |
|---|---|---|---|---|---|---|
| Sledge GW14 | 669 | 83 | – | 35% vs 16% | 16.4 vs 9.3 | – |
| Zaman K15 | 42 | 100 | – | 5% vs 15% | 3.7 vs 5.6 | 22.9 vs 19.4 |
| Adelson K23 | 116 | 100 | – | – | 2.73 vs 2.69 | – |
| Cristofanilli M12 | 521 | 79 | – | 19% vs 9% | 9.5 vs 4.6 | – |
| Hyams DM24 | 62 | 100 | NA | 22% vs 8% | 7.4 vs 3.7 | – |
| Burstein HJ16 | 291 | 100 | ±18% | 20% vs 9% | 4.7 vs 3.8 | 30 vs 26.4 |
| Clemons MJ17 | 129 | 100 | ±5% | 0% vs 7% | 5.8 vs 4.8 | 31 vs – |
| Musolino A25 | 97 | 100 | – | 28% vs 10% | 5.5 vs 5.5 | – |
| Baselga J13 | 1,147 | 100 | – | 12% vs 8% | 6.9 vs 5.0 | – |
| Kornblum NS26 | 130 | 100 | – | – | 10.4 vs 5.1 | – |
| Krop IE27 | 168 | 100 | – | 8% vs 6% | 6.6 vs 5.1 | – |
| Di Leo A28 | 432 | 100 | – | 8% vs 2% | 3.9 vs 1.8 | – |
| Robertson JF29 | 156 | 100 | ±7% | – | 3.7 vs 5.4 | – |
Abbreviations: HER2, human epidermal growth factor receptor 2; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; NA, not available.